Capricor Therapeutics is actively recruiting participants for a clinical trial for a potential cardiac cell therapy for those with Duchenne muscular dystrophy. CureDuchenne funded Capricor to support this trial that addresses heart disease, which is the primary cause of death for those with Duchenne.
The Halt cardiOmyopathy ProgrEssion in Duchenne (HOPE-Duchenne) is a clinical trial that will evaluate whether an investigational cardiac cell therapy (CAP-1002) is safe and potentially effective in treating boys and men with Duchenne associated heart disease. The HOPE trial will also study the amount of scar tissue in the heart muscle before and after infusion of the investigational cardiac cell therapy compared to scar remaining after usual care.
To participate in the study, patients need to be 12 years or older, have a document diagnosis of Duchenne and have heart disease due to Duchenne. The study involves:
- Questions about your medical history and some simple measure of muscle function
- Check-ups including blood tests
- Heart tests including a short ECG, a heart MRI and a heart monitor worn at home
- Breathing tests
For more information, review the HOPE-Duchenne brochure and Q&A. You can learn more about this trial at: https://clinicaltrials.gov/ct2/show/NCT02485938?term=capricor+duchenne&rank=1
CureDuchenne continues to fund impactful research and clinical trials that help treat the whole disease, including cardiac issues. We will continue to lead in drug development for Duchenne until there is a cure. Our mission is to treat all those with Duchenne, regardless of mutation.